ALTIRIS THERAPEUTICS

altiris-therapeutics-logo

Altiris Therapeutics develops and commercializes drugs to treat metastatic cancer. The company offers CXCR4 receptor, which acts as a mediator of cellular and chemical trafficking; and Emtriva, which is used for the treatment of HIV Infection. Altiris Therapeutics was founded in 2005 and is based in Atlanta, Georgia.

#SimilarOrganizations #People #Financial #More

ALTIRIS THERAPEUTICS

Industry:
Biotechnology Health Care Medical Therapeutics

Founded:
2005-01-01

Address:
Atlanta, Georgia, United States

Country:
United States

Total Employee:
501+

Status:
Active

Contact:
(404) 537-4961

Total Funding:
46.34 M USD


Similar Organizations

bone-rad-therapeutics-logo

Bone-Rad Therapeutics

Bone-Rad Therapeutics is a Delaware corporation whose objective is to develop and market brachytherapy bone cement to treat tumors in bone.

chimeron-bio-logo

Chimeron Bio

Chimeron Bio develops agents for personalized cancer gene therapy.

targeted-cancer-therapeutics-logo

Targeted Cancer Therapeutics

Targeted Cancer Therapeutics develops therapies for treating cancer.

transcardiac-therapeutics-logo

TransCardiac Therapeutics

TransCardiac Therapeutics develops technologies to facilitate access to the human heart.

verismo-therapeutics-logo

Verismo Therapeutics

Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.


Current Advisors List

chris-kroeger_image

Chris Kroeger Board of Observer @ Altiris Therapeutics
Board_observer

not_available_image

James Snyder Member of Scientific Advisor @ Altiris Therapeutics
Advisor

andy-jane_image

Andy Jane Director @ Altiris Therapeutics
Board_member

Current Employees Featured

not_available_image

James Snyder
James Snyder Co-Founder @ Altiris Therapeutics
Co-Founder

dennis-c-liotta_image

Dennis C. Liotta
Dennis C. Liotta Co-Founder @ Altiris Therapeutics
Co-Founder

not_available_image

Hyunsuk Shim
Hyunsuk Shim Co-Founder @ Altiris Therapeutics
Co-Founder

Founder


dennis-c-liotta_image

Dennis C. Liotta

not_available_image

Hyunsuk Shim

not_available_image

James Snyder

Investors List

atdc_image

ATDC

ATDC investment in Venture Round - Altiris Therapeutics

atdc_image

ATDC

ATDC investment in Series C - Altiris Therapeutics

atdc_image

ATDC

ATDC investment in Series B - Altiris Therapeutics

georgia-venture-partners_image

Georgia Venture Partners

Georgia Venture Partners investment in Series B - Altiris Therapeutics

centrosome-ventures_image

Centrosome Ventures

Centrosome Ventures investment in Series B - Altiris Therapeutics

frazier-healthcare-ventures_image

Frazier Healthcare Partners

Frazier Healthcare Partners investment in Series B - Altiris Therapeutics

cm-capital-investments_image

Talu Ventures

Talu Ventures investment in Series B - Altiris Therapeutics

hig-capital_image

H.I.G. Capital

H.I.G. Capital investment in Series B - Altiris Therapeutics

sr-one_image

SR One

SR One investment in Series B - Altiris Therapeutics

medimmune-ventures_image

MedImmune Ventures

MedImmune Ventures investment in Series B - Altiris Therapeutics

More informations about "Altiris Therapeutics"

Altiris Therapeutics - Crunchbase Company Profile & Funding

Altiris Therapeutics develops and commercializes drugs to treat metastatic cancer. The company offers CXCR4 receptor, which acts as a mediator of cellular and chemical trafficking; and โ€ฆSee details»

Altiris Therapeutics, Inc.: Drug pipelines, Patents, Clinical trials ...

Jun 21, 2023ย ยท Explore Altiris Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, and 1 literature, Technology Platform:Small molecule drug, โ€ฆSee details»

Altiris Therapeutics Inc - Company Profile and News

Company profile page for Altiris Therapeutics Inc including stock price, company news, executives, board members, and contact informationSee details»

Altiris Therapeutics - Company Profile - Tracxn

Altiris Therapeutics - CXCR4 receptor antagonist for solid tumors. This company is not active anymore. Raised a total funding of $37.5M over 2 rounds from 9 investors. Founded by Dennis โ€ฆSee details»

Altiris Therapeutics, Inc.:Company Profile & Technical Research ...

Altiris Therapeutics, Inc. is a company that provides Drug, Pharmacy and Therapeutics, CXCR4 and more. Altiris Therapeutics, Inc. is headquartered in United States Georgia. Altiris โ€ฆSee details»

Altiris Therapeutics - Funding, Financials, Valuation & Investors

Altiris Therapeutics develops and commercializes drugs to treat metastatic cancer.See details»

Altiris Therapeutics funding & investors - Tracxn

Nov 4, 2024ย ยท Altiris Therapeutics has raised a total funding of $37.5M over 2 rounds from 9 investors. Investors include Frazier Healthcare Partners, SR One and 7 others. Their latest โ€ฆSee details»

Altiris Therapeutics - Updates, News, Events, Signals & Triggers

Altiris Therapeutics develops and commercializes drugs to treat metastatic cancer.See details»

Altiris Therapeutics - Products, Competitors, Financials, Employees ...

Developer of small molecule therapeutics for the treatment of aggressive and refractory metastatic cancers and inflammation. Use the CB Insights Platform to explore Altiris Therapeutics's full โ€ฆSee details»

Altiris Therapeutics Inc. - BioCentury Company Profiles - BCIQ

Website: http://www.altiristherapeut... Historical deals and financings can be found by searching the organization's name in the BCIQ Deals and Financing Modules.See details»

Drug Discovery Companies | Emory University | Atlanta GA

Company Profile: Altiris Therapeutics, Inc. developed and commercialized orally administered small-molecule drug therapies. The company was developing drugs that inhibit CXCR4, a โ€ฆSee details»

Altiris Therapeutics Stock Price, Funding, Valuation, Revenue ...

See Altiris Therapeutics funding rounds, investors, investments, exits and more. Evaluate their financials based on Altiris Therapeutics's post-money valuation and revenue.See details»

Patents Assigned to Altiris Therapeutics, Inc.

Nov 15, 2012ย ยท Applicant: ALTIRIS THERAPEUTICS, INC. Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts, solvates, tautomers, โ€ฆSee details»

Altiris Therapeutics CEO, Founder, Key Executive Team, Board of ...

Explore {Altiris Therapeutics's key management people. Discover current leadership team members including founders, CEO, other executives and board directors.See details»

Altiris Therapeutics - Contacts, Employees, Board Members, โ€ฆ

Altiris Therapeutics develops and commercializes drugs to treat metastatic cancer.See details»

ALT-1188: A New CXCR4 Antagonist In Development For โ€ฆ

Nov 15, 2013ย ยท Methods: We tested four nonpeptide CXCR4 antagonists (ALT1188, 1187, 1128, and 1228) with low molecular weights and a novel and simple scaffold: an azacarbazole, โ€ฆSee details»

Research programme: CXCR4 antagonists - Altiris Therapeutics

Nov 6, 2014ย ยท Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. Metastatix (now Altiris Therapeutics) was discovering and โ€ฆSee details»

Q 122 - AdisInsight - Springer

Nov 29, 2022ย ยท Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.See details»

Altiris Therapeutics - Crunchbase

Altiris Therapeutics develops and commercializes drugs to treat metastatic cancer.See details»

ALT-1188: A New CXCR4 Antagonist In Development For

Nov 15, 2013ย ยท Methods: We tested four nonpeptide CXCR4 antagonists (ALT1188, 1187, 1128, and 1228) with low molecular weights and a novel and simple scaffold: an azacarbazole, โ€ฆSee details»

linkstock.net © 2022. All rights reserved